Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 145

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action

Battram, Cliff, Charlton, Steven J., Cuenoud, Bernard, Dowling, Mark R., Fairhurst, Robin A., Farr, David, Fozard, John R., Leighton-Davies, Juliet R., Lewis, Christine A., McEvoy, Lorraine, Turner, Robert J., Trifilieff, Alexandre·2006·The Journal of Pharmacology and Experimental Therapeutics

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/jpet.105.098251

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 29

  1. Anderson GP, Linden A, and Rabe KF (1994) Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7: 569-578. · doi:10.1183/09031936.94.07030569
  2. Bennett JA, Smyth ET, Pavord ID, Wilding PJ, and Tattersfield AE (1994) Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 49: 771-774. · doi:10.1136/thx.49.8.771
  3. Chong BTY, Agrawal DK, Romero FA, and Townley RG (1998) Measurement of bronchoconstriction using whole-body plethysmograph: comparison of freely moving versus restrained guinea pigs. J Pharmacol Toxicol Methods 39: 163-168. · DOI
  4. Coleman RA and Nials AT (1989) Novel and versatile superfusion system. Its use in the evaluation of some spasmogenic and spasmolytic agents using guinea-pig isolated tracheal smooth muscle. J Pharmacol Methods 21: 71-86. · doi:10.1016/0160-5402(89)90023-5
  5. Fozard JR and Buescher H (2001) Comparison of the anti-bronchoconstrictor activities of inhaled formoterol, its (R,R)- and (S,S)-enantiomers and salmeterol in the rhesus monkey. Pulm Pharmacol Ther 14: 289-295. · doi:10.1006/pupt.2001.0295
  6. Gauthier C, Langin D, and Balligand JL (2000) Beta3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21: 426-431. · DOI · Paper page
  7. Gross NJ (2004) Tiotropium bromide. Chest 126: 1946-1953. · DOI
  8. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, and Tattersfield AE (2000) Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 55: 650-656. · DOI
  9. Kalra S, Swystun VA, Bhagat R, and Cockcroft DW (1996) Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 109: 953-956. · DOI
  10. Kanniess F, Cameron R, Owen R, and Higgins M (2005) Indacaterol, a novel once-daily β2-agonist, demonstrates 24-hours efficacy and is well tolerated in patients with persistent asthma: a multiple-dose, dose-ranging study. Eur Respir J 26: 253s. · doi:10.1016/j.jaci.2005.12.776
  11. Larj MJ and Bleecker ER (2002) Effects of beta 2-agonists on airway tone and bronchial responsiveness. J Allergy Clin Immunol 110: S304-S312. · DOI
  12. Levine MA and Leenen FH (1989) Role of beta 1-receptors and vagal tone in cardiac inotropic and chronotropic responses to a beta 2-agonist in humans. Circulation 79: 107-115. · doi:10.1161/01.cir.79.1.107
  13. Lipworth BJ and Grove A (1997) Evaluation of partial beta-adrenoceptor agonist activity. Br J Clin Pharmacol 43: 9-14. · doi:10.1111/j.1365-2125.1997.tb00025.x
  14. Lotvall J (2002) The long and short of beta 2-agonists. Pulm Pharmacol Ther 15: 497-501. · doi:10.1006/pupt.2002.0400
  15. Molimard M, Naline E, Zhang Y, Le Gross V, Begaud B, and Advenier C (1998) Long- and short-acting beta 2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J 11: 583-588. · doi:10.1183/09031936.98.11030583
  16. Motomura S, Reinhard-Zerkowski H, Daul A, and Brodde OE (1990) On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. Am Heart J 119: 608-619. · doi:10.1016/s0002-8703(05)80284-4
  17. Nials AT, Ball DI, Butchers PR, Coleman RA, Humbles AA, Johnson M, and Vardey CJ (1994) Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 251: 127-135. · DOI
  18. Nials AT, Coleman RA, Johnson M, Magnussen H, Rabe KF, and Vardey CJ (1993) Effects of beta-adrenoceptor agonists in human bronchial smooth muscle. Br J Pharmacol 110: 1112-1116. · doi:10.1111/j.1476-5381.1993.tb13929.x
  19. Rabe KF (2001) Formoterol in clinical practice-safety issues. Respir Med 95 (Suppl B): S21-S25. · doi:10.1053/rmed.2001.1142
  20. Sarria B, Naline E, Zhang Y, Cortijo J, Molimard M, Moreau J, Therond P, Advenier C, and Morcillo EJ (2002) Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus. Am J Physiol 283: L1125-L1132. · DOI
  21. Sovani MP, Whale CI, and Tattersfield AE (2004) A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Drug Saf 27: 689-715. · doi:10.2165/00002018-200427100-00001
  22. Stoloff S, Poinsett-Holmes K, and Dorinsky PM (2002) Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management. Pharmacotherapy 22: 212-226. · DOI
  23. Sutherland ER (2004) Outpatient treatment of chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol 114: 715-724. · DOI
  24. Tennant RC, Erin EM, Barnes PJ, and Hansel TT (2003) Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curr Opin Pharmacol 3: 270-276. · DOI
  25. van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, and Maesen FP (1996) Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 9: 1684-1688. · doi:10.1183/09031936.96.09081684
  26. Wardlaw A, Larivee P, Eller J, Cockcroft DW, Ghaly L, and Harris AG (2004) Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 93: 49-55. · DOI
  27. Wegener T, Hedenstrom H, and Melander B (1992) Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 102: 535-538. · doi:10.1378/chest.102.2.535
  28. White M and Sander N (1999) Asthma from the perspective of the patient. J Allergy Clin Immunol 104: 47-52. · doi:10.1016/s0091-6749(99)70273-3
  29. Ying Y, Leung KM, Berkbigler D, Halbert RJ, and Legorreta AP (1999) Compliance with US asthma management guidelines and specialty care: a regional variation or national concern? J Eval Clin Pract 5: 213-221. · DOI

Cited by

See all 145

Metadata

Authors
Battram, C., Charlton, S. J., Cuenoud, B., Dowling, M. R., Fairhurst, R. A., Farr, D., Fozard, J. R., Leighton-Davies, J. R., Lewis, C. A., McEvoy, L., Turner, R. J., & Trifilieff, A.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2006-05
Volume
317
Issue
2
Pages
762-770
ISSN
0022-3565
Cited by
145
References
2
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action. https://app.cochat.ai/papers/10.1124/jpet.105.098251
The paper
Battram, C., Charlton, S. J., Cuenoud, B., Dowling, M. R., Fairhurst, R. A., Farr, D., Fozard, J. R., Leighton-Davies, J. R., Lewis, C. A., McEvoy, L., Turner, R. J., & Trifilieff, A. (2006). In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.105.098251

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.